Prelude Therapeutics Incorporated - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
PRLD Nasdaq 2836 preludetx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Prelude Therapeutics Incorporated

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Sep 11th, 2026 5:01 am
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader - Sep 10th, 2026 5:01 am
Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential - Aug 12th, 2026 10:07 am
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Aug 11th, 2026 5:00 am
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High? - Jul 31st, 2026 7:55 am
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why - Jul 17th, 2026 10:00 am
Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD) - May 31st, 2026 4:55 am
Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - May 16th, 2026 8:22 am
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 12th, 2026 5:01 am
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet - May 8th, 2026 7:55 am
Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer - May 1st, 2026 3:24 am
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 - Apr 20th, 2026 4:00 am
3 Best Vanguard Dividend ETFs for Reliable Passive Income in 2026 - Apr 16th, 2026 12:04 pm
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer - Apr 15th, 2026 5:30 am
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting - Mar 17th, 2026 2:31 pm
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 - Mar 10th, 2026 5:01 am
Sana Biotechnology (SANA) Appoints Industry Veteran Brian Piper as New CFO - Feb 26th, 2026 12:27 pm
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor - Feb 3rd, 2026 7:00 am
Definitive Healthcare And 2 Other Promising Penny Stocks - Jan 28th, 2026 11:05 am